Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)

被引：0
|
作者：
Nelson, J. B.
Chin, J. L.
Love, W.
Schulman, C.
Sleep, D.
Qian, J.
Steinberg, J.
Hintzman, P.
Dawson, M.
Carducci, M.
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Urol Res Ctr, Burlington, ON, Canada
[4] Hop Erasme, Brussels, Belgium
[5] Abbott, Abbott Pk, IL USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [22] RETROSPECTIVE EVALUATION OF THERAPY WITH KETOCONAZOLE IN HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Bonetta, Alberto
    Derelli, Roberto
    ANTICANCER RESEARCH, 2011, 31 (05) : 1942 - 1943
  • [23] A phase II trial of irinotecan in hormone-refractory prostate cancer
    Reese, DM
    Tchekmedyian, S
    Chapman, Y
    Prager, D
    Rosen, PJ
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 353 - 359
  • [24] Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients
    Prezioso, Domenico
    Galasso, Raffaele
    Di Martino, Mario
    Iapicca, Gennaro
    Annunziata, Emanuele
    Iacono, Fabrizio
    ANTICANCER RESEARCH, 2007, 27 (02) : 1095 - 1104
  • [25] Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC)
    Papatsoris, AG
    Karamouzis, MV
    Papavassiliou, AG
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (03) : 277 - 296
  • [26] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [27] A phase II trial of irinotecan in hormone-refractory prostate cancer
    David M. Reese
    Simon Tchekmedyian
    Yvonne Chapman
    Diane Prager
    Peter J. Rosen
    Investigational New Drugs, 1998, 16 : 353 - 359
  • [28] Vinflunine (VFL) as salvage chemotherapy in hormone-refractory prostate cancer (HRPC)
    Meluch, A. A.
    Spigel, D. R.
    Burris, H. A., III
    Greco, F. A.
    Gandhi, J.
    Crane, E.
    Markus, T. M.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] The Dynamics of PSA during Hormone-Refractory Prostate Cancer (HRPC) Chemotherapy (CT)
    Sergeeva, N. S.
    Marshutina, N. V.
    Bolotina, L. V.
    Parilova, N. K.
    TUMOR BIOLOGY, 2008, 29 : 49 - 49
  • [30] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
12345